Course of Health Science, Hyogo Medical University Graduate School of Health Science, Kobe, Japan.
Department of Physical Therapy, School of Rehabilitation, Hyogo Medical University, Kobe, Japan.
J Cachexia Sarcopenia Muscle. 2022 Dec;13(6):2898-2907. doi: 10.1002/jcsm.13078. Epub 2022 Sep 4.
Patients with end-stage renal disease (ESRD) are at an increased risk of developing sarcopenia, which can lead to various adverse health outcomes. Although the diagnosis of sarcopenia is essential for clinical management, it is not feasible in routine clinical practice for populations undergoing haemodialysis because it is time-consuming and resources are limited. Serum creatinine levels in patients with ESRD have been gaining attention as a screening parameter for sarcopenia because serum creatinine is a routinely measured byproduct of skeletal muscle metabolism. This study aimed to evaluate the discriminative ability of the creatinine-derived index for sarcopenia in patients undergoing haemodialysis.
We diagnosed sarcopenia according to the Asian Working Group for Sarcopenia (AWGS) 2 criteria in 356 clinically stable outpatients with ESRD enrolled from three dialysis facilities. We adopted the modified creatinine index as a simplified discriminant parameter for sarcopenia in addition to the calf circumference, SARC-F score, and combination of both (i.e. SARC-CalF score), which are recommended by the AWGS. Receiver operating characteristic analysis and logistic regression analysis were conducted to evaluate the discriminative ability of the modified creatinine index for sarcopenia.
Of the study participants, 142 (39.9%) were diagnosed with sarcopenia. The areas under the curve of the modified creatinine index against sarcopenia in the male and female participants were 0.77 (95% confidence interval [CI]: 0.71 to 0.83) and 0.77 (95% CI: 0.69 to 0.85), respectively. All simplified discriminant parameters were significantly associated with sarcopenia, even after adjusting for patient characteristics and centre. In the comparison of the odds ratios for sarcopenia for 1-standard deviation change in the simplified discriminant parameters, the odds ratio of the modified creatinine index was 1.92 (95% CI: 1.15 to 3.19), which was lower than that of the calf circumference (odds ratio: 6.58, 95% CI: 3.32 to 13.0) and similar to that of the SARC-F (odds ratio: 1.57, 95% CI: 1.14 to 2.16) and SARC-CalF scores (odds ratio: 2.36, 95% CI: 1.60 to 3.47).
This study revealed a strong association between the creatinine-derived index and sarcopenia in patients undergoing haemodialysis. The modified creatinine index was equal or superior to those of SARC-F and SARC-CalF score in discriminability for sarcopenia. However, the ability of the calf circumference to discriminate sarcopenia is extremely high, and further study is needed to determine whether it can be used to detect deterioration of muscle mass and function over time.
终末期肾病(ESRD)患者发生肌少症的风险增加,肌少症可导致各种不良健康结局。虽然肌少症的诊断对于临床管理至关重要,但由于耗时且资源有限,对于接受血液透析的人群,在常规临床实践中无法进行诊断。ESRD 患者的血清肌酐水平作为肌少症的筛查参数受到关注,因为血清肌酐是骨骼肌代谢的常规测量副产品。本研究旨在评估血液透析患者肌少症的肌酐衍生指数的鉴别能力。
我们根据亚洲肌少症工作组(AWGS)2 标准,对来自 3 家透析机构的 356 名临床稳定的 ESRD 门诊患者进行肌少症诊断。除 AWGS 推荐的小腿围、SARC-F 评分和两者的组合(即 SARC-CalF 评分)外,我们采用改良的肌酐指数作为肌少症的简化判别参数。进行受试者工作特征分析和逻辑回归分析,以评估改良肌酐指数对肌少症的鉴别能力。
在研究参与者中,142 人(39.9%)被诊断为肌少症。男性和女性参与者改良肌酐指数对肌少症的曲线下面积分别为 0.77(95%置信区间[CI]:0.71 至 0.83)和 0.77(95% CI:0.69 至 0.85)。所有简化判别参数均与肌少症显著相关,即使在调整了患者特征和中心后也是如此。在比较简化判别参数的 1 标准差变化对肌少症的比值比时,改良肌酐指数的比值比为 1.92(95%CI:1.15 至 3.19),低于小腿围(比值比:6.58,95%CI:3.32 至 13.0),与 SARC-F(比值比:1.57,95%CI:1.14 至 2.16)和 SARC-CalF 评分(比值比:2.36,95%CI:1.60 至 3.47)相似。
本研究揭示了血液透析患者的肌酐衍生指数与肌少症之间的强烈关联。改良的肌酐指数在肌少症的鉴别能力方面与 SARC-F 和 SARC-CalF 评分相等或更高。然而,小腿围的鉴别能力极高,需要进一步研究以确定它是否可以用于检测随时间推移肌肉质量和功能的恶化。